This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 104/2/265    most recent CIRCRESAHA.108.190397v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Donaldson, C. Articles by Patten, R. D. Search for Related Content PubMed PubMed Citation Articles by Donaldson, C. Articles by Patten, R. D. Related Collections Contractile function Congestive Remodeling Animal models of human disease Heart failure - basic studies Hypertrophy Physiological and pathological control of gene expression

(Circulation Research. 2009;104:265.)
© 2009 American Heart Association, Inc.

Integrative Physiology

Estrogen Attenuates Left Ventricular and Cardiomyocyte Hypertrophy by an Estrogen Receptor–Dependent Pathway That Increases Calcineurin Degradation

Cameron Donaldson^*, Sarah Eder^*, Corey Baker^*, Mark J. Aronovitz, Alexandra Dabreo Weiss, Monica Hall-Porter, Feng Wang, Adam Ackerman, Richard H. Karas, Jeffery D. Molkentin, Richard D. Patten

From the Molecular Cardiology Research Institute (C.D., S.E., C.B., M.J.A., A.D.W., M.H.-P., F.W., A.A., R.H.K., R.D.P.), Tufts Medical Center, Boston, Mass; and Molecular Cardiovascular Biology Division (J.D.M.), Department of Pediatrics, Cincinnati Children’s Medical Center, Ohio.

Correspondence to Richard D. Patten, MD, Assistant Professor of Medicine, Department of Medicine, Tufts–New England Medical Center, 750 Washington St, Boston, MA 02111. E-mail rpatten{at}tuftsmedicalcenter.org

Left ventricular (LV) hypertrophy commonly develops in response to chronic hypertension and is a significant risk factor for heart failure and death. The serine-threonine phosphatase calcineurin (Cn)A plays a critical role in the development of pathological hypertrophy. Previous experimental studies in murine models show that estrogen limits pressure overload–induced hypertrophy; our purpose was to explore further the mechanisms underlying this estrogen effect. Wild-type, ovariectomized female mice were treated with placebo or 17β-estradiol (E2), followed by transverse aortic constriction (TAC), to induce pressure overload. At 2 weeks, mice underwent physiological evaluation, immediate tissue harvest, or dispersion of cardiomyocytes. E2 replacement limited TAC-induced LV and cardiomyocyte hypertrophy while attenuating deterioration in LV systolic function and contractility. These E2 effects were associated with reduced abundance of CnA. The primary downstream targets of CnA are the nuclear factor of activated T-cell (NFAT) family of transcription factors. In transgenic mice expressing a NFAT-activated promoter/luciferase reporter gene, E2 limited TAC-induced activation of NFAT. Moreover, the inhibitory effects of E2 on LV hypertrophy were absent in CnA knockout mice, supporting the notion that CnA is an important target of E2-mediated inhibition. In cultured rat cardiac myocytes, E2 inhibited agonist-induced hypertrophy while also decreasing CnA abundance and NFAT activation. Agonist stimulation also reduced CnA ubiquitination and degradation that was prevented by E2; all in vitro effects of estrogen were reversed by an estrogen receptor (ER) antagonist. These data support that E2 reduces pressure overload induced hypertrophy by an ER-dependent mechanism that increases CnA degradation, unveiling a novel mechanism by which E2 and ERs regulate pathological LV and cardiomyocyte growth.

Key Words: estrogen • left ventricular remodeling • pressure overload • myocyte hypertrophy • calcineurin proteasome • ubiquitin